Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Guaranteed Purchase Of All Doses Could Attract Flu Vaccine Makers, Wyeth Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Guaranteeing that all flu vaccine doses produced will be purchased is the most significant way Congress can create incentives for manufacturers to re-enter the flu vaccine market, Wyeth VP-Scientific Affairs Peter Paradiso, PhD, said Nov. 16

You may also be interested in...



3.5 Mil. Doses Of Sanofi-Aventis’ Fluzone Still Unused, CDC Says

HHS will wait to distribute GSK’s Fluarix until Fluzone supply is exhausted, Centers for Disease Control & Prevention Director Gerberding says. Some states have begun to relax recommendations so that people who are not in high priority groups can get vaccinated.

3.5 Mil. Doses Of Sanofi-Aventis’ Fluzone Still Unused, CDC Says

HHS will wait to distribute GSK’s Fluarix until Fluzone supply is exhausted, Centers for Disease Control & Prevention Director Gerberding says. Some states have begun to relax recommendations so that people who are not in high priority groups can get vaccinated.

FluMist May Require Additional Phase III Trial To Expand Patient Population

MedImmune seeks to expand the indication for its intranasal flu vaccine to people ages 50 to 64; the company is waiting to see if FDA will accept new analyses of existing data in the target age group. MedImmune and Chiron suggest incentives to increase flu vaccine demand during a House committee hearing.

Topics

UsernamePublicRestriction

Register

ID1131437

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel